A securities fraud class action notice highlights potential liability for Capricor Therapeutics and invites affected investors to seek lead plaintiff status
Executive summary: Investors who purchased Capricor Therapeutics (CAPR) shares between December 17, 2025 and July 26, 2026 were notified of an opportunity to serve as lead plaintiff in a securities fraud class action lawsuit announced by Kessler Topaz Meltzer & Check LLP. The lawsuit could result in financial liability for Capricor Therapeutics, affect its share price, and signal heightened regulatory oversight of biotech disclosures.
Who is involved: Capricor Therapeutics, Inc., its shareholders, and the law firm Kessler Topaz Meltzer & Check LLP are the primary parties.
Likely next: Plaintiffs will file a motion for lead plaintiff status before the court‑set deadline, after which the case may proceed to class certification and potential settlement negotiations.
The press release issued by Kessler Topaz Meltzer & Check LLP informs investors that they may seek appointment as lead plaintiff in a class action alleging securities fraud involving Capricor Therapeutics shares traded between December 2025 and July 2026. The notice does not detail the alleged misconduct but specifies the class period and the deadline for lead plaintiff motions. Such litigation can impose costs on the company and influence investor sentiment. The outcome will depend on court rulings regarding class certification and any eventual settlement.
What's next — scenarios
Class Certification Success (25%)
Increased legal reserves and heightened volatility in stock price due to settlement fears.
- Court grants class certification
- Appointment of a well-funded lead plaintiff
Dismissal of Complaint (50%)
Restoration of investor confidence and reduction in long-term litigation risk.
- Motion to dismiss is granted
- Court finds lack of scienter in filings
Negotiated Settlement (25%)
Immediate cash outflow and non-recurring legal expenses impacting net income.
- Preliminary settlement agreement filed
- Stipulation of settlement approved by judge
What to watch
- Court ruling on Motion to Dismiss (next 60 days)
- Appointment of Lead Plaintiff (next 45 days)
- Quarterly litigation reserve disclosures in SEC filings (next 90 days)
Timeline
- — ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP (PR Newswire)
- — GPGI, Inc. (NYSE: GPGI) Class Action Lawsuit Seeks Recovery for Investors; September 14, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP (PR Newswire)
Analysis — what this means
Sectors affected
- Biotechnology
Historical parallels
- GPGI class action lawsuit filed August 20, 2026, announced by Kessler Topaz Meltzer & Check LLP
Contradictions
- Title states ImmunityBio, Inc. (IBRX) as subject; excerpt states Capricor Therapeutics, Inc. (NASDAQ: CAPR) as subject.
Key entities
Sources
- ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP — PR Newswire
- GPGI, Inc. (NYSE: GPGI) Class Action Lawsuit Seeks Recovery for Investors; September 14, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP — PR Newswire
Related cases
- Edelson Lechtzin LLP launches investigation into possible class action over Millstone Medical Outsourcing data breach exposing personal and health data
- Edelson Lechtzin LLP launches class-action investigation into CAZ Investments LP data breach, part of a same-day wave of breach probes targeting multiple firms
- Edelson Lechtzin LLP launches class‑action probe after Atlantic Digestive Specialists exposes patient data
- Law firm Edelson Lechtzin LLP launches investigation into Poppins Payroll data breach, offering free case evaluations to affected users
- Edelson Lechtzin LLP investigates Saber Healthcare data breach, raising potential litigation and cybersecurity costs for the health provider
- Robbins Geller announces lead plaintiff deadline for AST SpaceMobile securities class action covering March 2025–July 2026 purchases